| Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised … S Rts The Lancet 386 (9988), 31-45, 2015 | 1260 | 2015 |
| First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children RTS, S Clinical Trials Partnership New England Journal of Medicine 365 (20), 1863-1875, 2011 | 1068 | 2011 |
| Oral versus intravenous antibiotics for bone and joint infection HK Li, I Rombach, R Zambellas, AS Walker, MA McNally, BL Atkins, ... New England Journal of Medicine 380 (5), 425-436, 2019 | 1012 | 2019 |
| A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. S Rts, ST Agnandji, B Lell, JF Fernandes, BP Abossolo, BG Methogo, ... The New England journal of medicine 367 (24), 2284-95, 2012 | 949 | 2012 |
| Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya WP O'Meara, P Bejon, TW Mwangi, EA Okiro, N Peshu, RW Snow, ... The lancet 372 (9649), 1555-1562, 2008 | 591 | 2008 |
| Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children A Olotu, G Fegan, J Wambua, G Nyangweso, A Leach, M Lievens, ... New England Journal of Medicine 374 (26), 2519-2529, 2016 | 570 | 2016 |
| Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age P Bejon, J Lusingu, A Olotu, A Leach, M Lievens, J Vekemans, S Mshamu, ... New England Journal of Medicine 359 (24), 2521-2532, 2008 | 566 | 2008 |
| Phase 1 trials of rVSV Ebola vaccine in Africa and Europe ST Agnandji, A Huttner, ME Zinser, P Njuguna, C Dahlke, JF Fernandes, ... New England Journal of Medicine 374 (17), 1647-1660, 2016 | 542 | 2016 |
| Genetic diversity and protective efficacy of the RTS, S/AS01 malaria vaccine DE Neafsey, M Juraska, T Bedford, D Benkeser, C Valim, A Griggs, ... New England Journal of Medicine 373 (21), 2025-2037, 2015 | 533 | 2015 |
| One hundred and twelve infected arthroplasties treated with ‘DAIR’(debridement, antibiotics and implant retention): antibiotic duration and outcome I Byren, P Bejon, BL Atkins, B Angus, S Masters, P McLardy-Smith, ... Journal of antimicrobial chemotherapy 63 (6), 1264-1271, 2009 | 519 | 2009 |
| Upregulation of TGF-β, FOXP3, and CD4+ CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection M Walther, JE Tongren, L Andrews, D Korbel, E King, H Fletcher, ... Immunity 23 (3), 287-296, 2005 | 505 | 2005 |
| Immunogenicity of the RTS, S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial MT White, R Verity, JT Griffin, KP Asante, S Owusu-Agyei, B Greenwood, ... The Lancet infectious diseases 15 (12), 1450-1458, 2015 | 450 | 2015 |
| Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites RTS, S Clinical Trials Partnership (2014) PLoS medicine 11 (7), e1001685, 2014 | 402 | 2014 |
| Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure A Olotu, G Fegan, J Wambua, G Nyangweso, KO Awuondo, A Leach, ... New England Journal of Medicine 368 (12), 1111-1120, 2013 | 386 | 2013 |
| Genetic diversity of the African malaria vector Anopheles gambiae Anopheles gambiae 1000 Genomes Consortium Nature 552 (7683), 96, 2017 | 372 | 2017 |
| Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion J Illingworth, NS Butler, S Roetynck, J Mwacharo, SK Pierce, P Bejon, ... The Journal of Immunology 190 (3), 1038-1047, 2013 | 370 | 2013 |
| Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors S Uyoga, IMO Adetifa, HK Karanja, J Nyagwange, J Tuju, P Wanjiku, ... Science 371 (6524), 79-82, 2021 | 362 | 2021 |
| Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis RM Mogire, A Mutua, W Kimita, A Kamau, P Bejon, JM Pettifor, ... The Lancet Global Health 8 (1), e134-e142, 2020 | 345 | 2020 |
| Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial MS Datoo, A Dicko, H Tinto, JB Ouédraogo, M Hamaluba, A Olotu, ... The Lancet 403 (10426), 533-544, 2024 | 343 | 2024 |
| Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya P Bejon, TN Williams, A Liljander, AM Noor, J Wambua, E Ogada, A Olotu, ... PLoS medicine 7 (7), e1000304, 2010 | 337 | 2010 |
Tabitha MwangiUniversity of CambridgeVerified email at cam.ac.uk
